Benzinga -
- Kymera Therapeutics Inc (NASDAQ: KYMR) announced clinical results from the patient cohort portion of its KT-474 (IRAK4) Phase 1 trial in hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients.
- KT-474 demonstrated robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety profile.
- KT-474 showed IRAK4 knockdown in blood and skin comparable to MAD3, with maximum degradation exceeding 90%. Target (NYSE:TGT) degradation was similar across HS and AD patients in blood and skin.
- In ex vivo cytokine stimulation assays, KT-474 demonstrated broad and deep inhibition of multiple disease-relevant cytokines, including inhibition of up to 84% in HS and up to 98% in AD.
- KT-474 also reduced several circulating cytokines and acute phase reactants in vivo.
- Sanofi (EPA:SASY) (NASDAQ: SNY), collaborating with Kymera on developing KT-474 (SAR444656) outside of the oncology and immune-oncology fields, has notified Kymera of its commitment to advance KT-474 into Phase 2 clinical studies.
- The initial Phase 2 trial of KT-474 will investigate its potential in HS and AD, with the first study initiating in 2023.
- Price Action: KYMR shares are up 22.2% at $31.57 on the last check Wednesday.
- Photo Via Company